Immunic, Inc., trading under the ticker symbol IMUX, executed a formal corporate stock split on April 27, 2026, structured specifically as a one-for-ten reverse stock split. This structural capital adjustment was officially approved by the board of directors and authorized by shareholders to consolidate the number of issued and outstanding common shares, thereby elevating the per-share trading price to maintain strict compliance with the minimum bid price listing requirements mandated by the Nasdaq Global Market. Such corporate actions are common among clinical-stage biotechnology firms whose share prices have drifted lower during prolonged developmental phases.